Brief: Dermapharm Holding SE - Outlook For 2024 Confirmed
Aug 27 (Reuters) - Dermapharm Holding SE DMPG.DE :
* OUTLOOK FOR 2024 CONFIRMED
* H1 EBITDA EUR 147 MILLION
* H1 UNADJUSTED EBITDA MARGIN 25.4%
* H1 REVENUE 578.5 MILLION EUR (H1 2023 582.1 MILLION EUR)
* H1 ADJUSTED EBITDA MARGIN 26.4%
Further company coverage: DMPG.DE
(Gdansk Newsroom)
(( gdansk.newsroom@thomsonreuters.com ; +48 58 7696600; ))
Recent news on Dermapharm Holding SE
See all newsBrief: Dermapharm Confirms 2026 Forecast
Corrected: Germany's Dermapharm prelim H1 revenue rises, maintains outlook
Brief: Dermapharm Holding - Confirms Full-Year Guidance For 2026
Brief: Dermapharm Spokesperson - Dermapharm Is Engaged In A Constructive Dialogue With The Regulator
Refile: BUZZ-Dermapharm Holding slips after BaFin's audit